research drug at science lab
Our Work

Latham & Watkins Advises Grünenthal on €300 Million Bond

April 20, 2023
German team represents leading pharmaceutical company on significant issuance.

Latham & Watkins has advised Grünenthal GmbH (Grünenthal), a leading pharmaceutical company in the area of pain management, on the issuance of €300 million bond aggregate principal amount of 6.75% senior secured notes due 2030.

The Latham team was led by Munich partner Rüdiger Malaun and Frankfurt partner Alexander Lentz, with Frankfurt counsel Gregory Walker and associate Laura Neumann. The Latham team worked closely with Grünenthal’s in-house team led by General Counsel Sebastian Köhler.

Endnotes